Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of
Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients
with advanced ovarian cancer.